Genomic landscape of multiple myeloma and its precursor conditions

The Main section identifies MGUS and SMM as precursor stages of MM, and the Results section ‘Molecular tumor age of MGUS/SMM’ estimates a median molecular tumor age of 33 years in the MM samples studied. These passages support a decades-long disease history in some cases, but they do not establish that every MM case passes through those precursor states or that every precursor state lasts decades before MM diagnosis. Page numbers are not available in our copy. (LLM, conf=0.85)

The Results section on mutational processes (page unavailable) reports that early mutations in patients with hyperdiploidy were enriched for SBS9, an AID-associated signature. The cell-of-origin Results (page unavailable) also says predictions using mutations acquired before genomic amplifications were consistent with mature B-cell differentiation. Neither passage establishes this pattern in virtually all HY cases or rules out a pre-germinal-center origin. (LLM, conf=0.86)

The Discussion (page unavailable) says the first oncogenic events occur in the second or third decades of life, and the Results identify hyperdiploidy as an initiating event in the tumors used for age estimation. The paper does not establish that additional trisomies and aneuploidies are acquired in subsequent decades; its Methods instead treat hyperdiploidy as a single event. (LLM, conf=0.86)

The Results sections on serially sampled SMM and structural variation link acquired KRAS/NRAS mutations and MYC translocations to progression. The mutational-processes section also describes APOBEC activity emerging after precursor initiation, while the genomic-score section reports more driver events at later disease stages. The paper does not establish that these four categories are the most commonly reported alterations in progressing multiple myeloma (page numbers unavailable in our copy). (LLM, conf=0.84)

The Results section, “The MM-like genomic score captures disease progression” (page unavailable), reports that MM-enriched alterations are more common in MM and that a higher MM-like score predicts progression in SMM. But low-risk SMM and MGUS still had median MM-like scores of 1, so the paper does not establish that these events are usually absent from stable or indolent MGUS/SMM. The serial-sampling Results report largely stable scores in non-progressors, not absence of the events. (LLM, conf=0.85)

The Results (‘The MM-like genomic score captures disease progression’; page unavailable) show that high-risk SMM has a median MM-like score equal to that of MM, supporting genomic similarity. But the Discussion says whether some SMM should be categorized as MM based on genomic features remains an open question. The paper does not establish that a significant fraction has already transformed. (LLM, conf=0.83)

The Discussion reports genomic drivers and genetic heterogeneity at the earliest MGUS/SMM stages, and the Results report MM-like features in low-risk SMM. However, the longitudinal Results follow MGUS and high-risk SMM examples; they do not establish that these patterns were observed in low-risk SMM several years before progression. (LLM, conf=0.84)

In Results, ‘Molecular tumor age of MGUS/SMM’ (page unavailable), the median estimated age at initiation is 38 years for SMM overall, while the median tumor age is 30 years for MGUS/SMM patients who progressed. The paper does not give a 30–40-year initiation estimate specifically for SMM that progresses to MM; the claim combines two different measures and populations. (LLM, conf=0.88)

The Results (‘Molecular tumor age of MGUS/SMM’; page unavailable) report sequencing-based timing estimates for MGUS, SMM and MM, and the Methods (‘Genomic data collection’; page unavailable) describe a large sequencing dataset and FISH translocation data obtained from a previous study. The paper supports temporal analysis across those three disease stages, but the cited passages do not establish three distinct groups through a temporal model combining FISH and DNA sequencing. (LLM, conf=0.78)

The Results section, ‘The MM-like genomic score captures disease progression’ (page unavailable), reports that 24 driver alterations were more common in MM than in the combined MGUS/SMM group. It does not establish that these features are underrepresented specifically in high-risk SMM compared with newly diagnosed MM; it reports the same median MM-like score of 3 for high-risk SMM and MM. (LLM, conf=0.84)